Co-Authors
This is a "connection" page, showing publications co-authored by Brian Boyarsky and Robin Avery.
Connection Strength
2.731
-
SARS-CoV-2 Messenger RNA Vaccine Immunogenicity in Solid Organ Transplant Recipients With Prior COVID-19. Transplantation. 2021 11 01; 105(11):e270-e271.
Score: 0.244
-
Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients. JAMA. 2021 06 01; 325(21):2204-2206.
Score: 0.237
-
Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients. JAMA. 2021 05 04; 325(17):1784-1786.
Score: 0.236
-
Safety of the First Dose of SARS-CoV-2 Vaccination in Solid Organ Transplant Recipients. Transplantation. 2021 05 01; 105(5):e56-e57.
Score: 0.236
-
Early Development and Durability of SARS-CoV-2 Antibodies Among Solid Organ Transplant Recipients: A Pilot Study. Transplantation. 2021 05 01; 105(5):e52-e53.
Score: 0.236
-
Evolving Impact of COVID-19 on Transplant Center Practices and Policies in the United States. Clin Transplant. 2020 12; 34(12):e14086.
Score: 0.226
-
Early national and center-level changes to kidney transplantation in the United States during the COVID-19 epidemic. Am J Transplant. 2020 11; 20(11):3131-3139.
Score: 0.224
-
Early Experiences With COVID-19 Testing in Transplantation. Transplant Direct. 2020 Jul; 6(7):e572.
Score: 0.222
-
Early impact of COVID-19 on transplant center practices and policies in the United States. Am J Transplant. 2020 07; 20(7):1809-1818.
Score: 0.220
-
Antibody Response to a Fourth Dose of a SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series. Transplantation. 2021 12 01; 105(12):e280-e281.
Score: 0.061
-
Safety and Reactogenicity of 2 Doses of SARS-CoV-2 Vaccination in Solid Organ Transplant Recipients. Transplantation. 2021 10 01; 105(10):2170-2174.
Score: 0.061
-
Antibody Response to Severe Acute Respiratory Syndrome-Coronavirus-2 Messenger RNA Vaccines in Liver Transplant Recipients. Liver Transpl. 2021 12; 27(12):1852-1856.
Score: 0.060
-
Immunogenicity and Reactogenicity After SARS-CoV-2 mRNA Vaccination in Kidney Transplant Recipients Taking Belatacept. Transplantation. 2021 09 01; 105(9):2119-2123.
Score: 0.060
-
Development of COVID-19 Infection in Transplant Recipients After SARS-CoV-2 Vaccination. Transplantation. 2021 09 01; 105(9):e104-e106.
Score: 0.060
-
SARS-CoV-2 messenger RNA vaccine antibody response and reactogenicity in heart and lung transplant recipients. J Heart Lung Transplant. 2021 12; 40(12):1579-1588.
Score: 0.060
-
Kidney Transplant Recipient Attitudes Toward a SARS-CoV-2 Vaccine. Transplant Direct. 2021 Jul; 7(7):e713.
Score: 0.059
-
Safety of the first dose of mRNA SARS-CoV-2 vaccines in patients with rheumatic and musculoskeletal diseases. Ann Rheum Dis. 2021 Mar 19.
Score: 0.058
-
Liver transplantation in the United States during the COVID-19 pandemic: National and center-level responses. Am J Transplant. 2021 05; 21(5):1838-1847.
Score: 0.057
-
Effects of COVID-19 pandemic on pediatric kidney transplant in the United States. Pediatr Nephrol. 2021 01; 36(1):143-151.
Score: 0.057
-
Identifying scenarios of benefit or harm from kidney transplantation during the COVID-19 pandemic: A stochastic simulation and machine learning study. Am J Transplant. 2020 11; 20(11):2997-3007.
Score: 0.056